What it's for (Indications)
- Historically, the combination of methyloestradiol and methyloestrenolone (e.
- g.
- , Gynaecosid) was employed primarily as a hormonal pregnancy test, relying on withdrawal bleeding as an indicator of non-pregnancy.
- It was also, albeit controversially and with limited evidence, sometimes prescribed for the management of threatened or recurrent miscarriage to provide hormonal support for maintaining pregnancy.
- However, it is crucial to state that current medical guidelines and regulatory bodies overwhelmingly advise against the use of this medication for any indication due to significant safety concerns, particularly regarding fetal exposure.
- Its use as a pregnancy test is entirely obsolete and dangerous, and its role in miscarriage management has been thoroughly discredited, with safer and more effective alternatives now available.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Historically, when this combination was in use, the dosage for hormonal pregnancy testing typically involved a single oral administration of the fixed-dose combination. For instance, a common regimen might have been one or two tablets containing specific amounts of methyloestradiol and methyloestrenolone, with observation for withdrawal bleeding within a few days. For threatened or recurrent miscarriage, the dosage and duration were highly variable and often prescribed for short periods in early pregnancy, such as one tablet daily for several days. It is paramount to reiterate that detailed dosage instructions are no longer relevant, as this medication is not recommended for current clinical practice due to severe adverse effects and is largely withdrawn from global markets. |
Safety & Warnings
Common Side Effects
- The use of methyloestradiol and methyloestrenolone can lead to a range of side effects, including common estrogen/progestin-related symptoms such as nausea, vomiting, breast tenderness or enlargement, headaches, dizziness, fluid retention, and changes in mood or libido.
- More serious, albeit less common, side effects could include venous thromboembolism (deep vein thrombosis, pulmonary embolism), arterial thromboembolism (stroke, myocardial infarction), hypertension, gallbladder disease, and liver dysfunction including cholestatic jaundice.
- However, the most critical and severe adverse effects, particularly when administered during pregnancy, relate to significant teratogenicity, leading to a heightened risk of serious congenital malformations in exposed fetuses, which is the primary reason for its widespread discontinuation and contraindication in modern medicine, overshadowing any potential benefits.
Serious Warnings
- Black Box Warning: BOXED WARNING: RISK OF CONGENITAL MALFORMATIONS AND FETAL HARM; NOT FOR USE IN PREGNANCY OR AS A PREGNANCY TEST Methyloestradiol and Methyloestrenolone (e.g., Gynaecosid) are associated with a HIGH AND SIGNIFICANT RISK of severe congenital malformations and adverse fetal outcomes when administered during pregnancy, particularly in the first trimester. This medication MUST NOT BE USED by pregnant women, women who may be pregnant, or women attempting to conceive. Exposure to this fixed-dose combination has been linked to a substantial increase in birth defects including, but not limited to, cardiovascular anomalies (e.g., ventricular septal defects), limb reduction defects, neural tube defects (e.g., anencephaly, spina bifida), urogenital abnormalities, and facial clefts. Furthermore, the use of Methyloestradiol and Methyloestrenolone as a hormonal pregnancy test is OBSOLETE, INEFFECTIVE, and DANGEROUS. Confirmation of pregnancy should be performed using highly accurate and safe biochemical or imaging methods. This medication is NOT RECOMMENDED FOR ANY CURRENT CLINICAL INDICATION due to its unacceptable risk-benefit profile, especially in light of safer and more effective therapeutic alternatives where applicable. Physicians and patients must be made aware of these severe risks. Prescribing this medication to women of childbearing potential requires absolute certainty regarding non-pregnancy and adequate contraception during therapy, though its overall use is strongly discouraged due to overwhelming safety concerns.
- The use of methyloestradiol and methyloestrenolone carries substantial and severe warnings, making its current clinical application highly unadvisable.
- Foremost among these is the profound risk of teratogenicity.
- Exposure to this combination during early pregnancy has been strongly associated with an increased incidence of serious congenital malformations, including but not limited to cardiovascular defects (e.
- g.
- , ventricular septal defects), limb reduction defects, neural tube defects (e.
- g.
- , anencephaly, spina bifida), urogenital anomalies, and facial clefts.
- Additionally, as a high-dose synthetic sex steroid, it carries general warnings associated with hormonal preparations, such as an increased risk of thromboembolic events (venous and arterial), exacerbation of existing cardiovascular conditions, liver enzyme elevations, and potential for adverse effects on glucose tolerance.
- Patients should be explicitly warned against using this medication, especially if there is any possibility of pregnancy due to its unacceptable risk profile.
How it Works (Mechanism of Action)
Methyloestradiol is a synthetic estrogen that exerts its effects by binding to estrogen receptors, promoting endometrial proliferation, and influencing various physiological processes mediated by estrogen. Methyloestrenolone is a synthetic progestogen, which, when administered after estrogen priming, induces secretory changes in the endometrium. In the context of its historical use as a hormonal pregnancy test, the combination aimed to induce a withdrawal bleed if the woman was not pregnant (due to the sudden drop in hormone levels after stopping the medication). If the woman was pregnant, the endogenous pregnancy hormones would maintain the endometrium, preventing withdrawal bleeding. For threatened miscarriage, the intended, but unproven and dangerous, mechanism was to provide supraphysiological levels of sex steroids to support the uterine environment and prevent spontaneous abortion, a practice no longer supported by evidence or safety standards.
Commercial Brands (Alternatives)
No other brands found for this formula.